Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Source: Senate LDA
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
More Efficient Tools to Realize Information for Consumers Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
More Efficient Tools to Realize Information for Consumers Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
More Efficient Tools to Realize Information for Consumers Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable Prescriptions for Patients Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Affordable Prescriptions for Patients Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Affordable Prescriptions for Patients Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Lower Health Care Costs Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Lower Health Care Costs Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Lower Health Care Costs Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Safe and Affordable Drugs from Canada Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Agriculture Improvement Act of 2018
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate = Agriculture Improvement Act of 2018 (S.3042) House = Agriculture and Nutrition Act of 2018 (H.R. 2)
Agriculture Improvement Act of 2018
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate - Agriculture Improvement Act of 2018 (S. 3042) House - Agriculture and Nutrition Act of 2018 (H.R. 2)
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass- Through Status in Part B H.R. 6642 - Amend Title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs Manufacturer Liability in the Medicare Part D Donut Hole
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
Agriculture Improvement Act of 2018
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate = Agriculture Improvement Act of 2018 (S.3042) House = Agriculture and Nutrition Act of 2018 (H.R. 2)
Agriculture Improvement Act of 2018
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate - Agriculture Improvement Act of 2018 (S. 3042) House - Agriculture and Nutrition Act of 2018 (H.R. 2)
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Importation - Affordable and Safe Prescription Drug Importation Act (S469)
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; S. Con. Res. 3 and HR/245 & S.469 House and Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness COPD Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; S. Con. Res. 3 and HR/245 & S.469 House and Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness COPD Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3-2017 Budget Presidents 2018 Budget Blue Print; Presidents American Patients First Blueprint Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Pesticide Registration Improvement Act (PRIA) Farm Bill Implementation
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pesticide Registration Improvement Act (PRIA) Farm Bill Implementation
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Pesticide Registration Improvement Act (PRIA) Farm Bill Implementation
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
Trade Agreements including NAFTA, USMCA, and related policy issues Intellectual Property and Market Access Policy Issues
Pesticide Registration Improvement Act (PRIA) Farm Bill Implementation
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, U.S. Trade & Development Agency (USTDA)
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3-2017 Budget Presidents 2018 Budget Blue Print; Presidents American Patients First Blueprint Bipartisan Budget Act of 2018
Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate - Agriculture Improvement Act of 2018 (S. 3042) House - Agriculture and Nutrition Act of 2018 (H.R. 2)
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass- Through Status in Part B H.R. 6642 - Amend Title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs Manufacturer Liability in the Medicare Part D Donut Hole
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Importation - Affordable and Safe Prescription Drug Importation Act (S469)
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print; President's American Patients First Blueprint Bipartisan Budget Act of 2018
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness and Chronic Pulmonary Disease Awareness
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
House & Senate Budget Bills; Rebates for Dual Eligible, Low Income Subsidy Populations and Drug Pricing in the following: S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print Bipartisan Budget Act of 2018
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; IPAB (Independent Payment Advisory Board); Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; S. Con. Res. 3 and HR/245 & S.469 House and Senate bills titled the Affordable Safe and Prescription Drug Importation Act. Diabetes and Heart Health Awareness COPD Awareness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank Senate = Agriculture Improvement Act of 2018 (S.3042) House = Agriculture and Nutrition Act of 2018 (H.R. 2)
Average Sales Price; Reimbursement; CMS Rule coding for Biosimilars; Biosimilars and the Part D Coverage Gap Discount; Biosimilars Pass-Through Status in Part B
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Animal Health - The Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Farm Bill - U.S. Foot and Mouth Disease Vaccine Bank
Anti-Counterfeiting; S.469 - The Affordable and Safe Drug Importation Act
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE